Status: Not yet recruiting
Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma
This multicenter, open-label, externally controlled clinical study is designed to evaluate the safety and efficacy of CHANK-101, an autologous natural killer (NK) cell therapy, in patients with recurrent glioblastoma. The primary objective is to evaluate progression-free survival (PFS) following CHANK-101 administration. Secondary objectives include evaluating safety and tolerability, progression-free survival at 6 months (PFS-6), and overall survival (OS).
Participants needed: 60
Trial details
Age: 19-69Biological sex: AllType: InterventionalSponsor: Dong-A University HospitalUpdated: Sep 21, 2026Locations: 4
Eligibility criteria
Male or female adults aged 19 years to less than 70 years who have received suff... [+8]
Two or more recurrences or prior antitumor treatment for a previous recurrence. [+3]